Douglas Hay, PhD, is a pharmaceutical executive with more than 20 years of experience in drug discovery with GlaxoSmithKline (GSK). Dr. Hay has particular expertise in respiratory and inflammatory disease therapeutic areas and was most recently Vice President of the Chronic Obstructive Pulmonary Disease (COPD) Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery. In his time at GSK, Hay and his staff identified more than 25 compounds selected for development, with 1 approved, 1 NDA filed, and 1 compound completing Phase III clinical trials. He is the author of over 100 peer-reviewed papers, more than 40 book chapters and reviews, and has co-edited 2 books.

Dr. Hay obtained his Ph.D. in Physiology and Pharmacology from the University of Strathclyde, Scotland.